InvestorsHub Logo

CrashOverride

06/14/22 12:42 PM

#486600 RE: flipper44 #486598

These high prices exist pre-approval to spur innovation. If firms couldn't charge this much during an expensive R&D phase then there wouldn't be risk takers trying to defeat this insidious cancer!

The prices being charged now in specials, with zero economies of scale or NICE leverage in negotiating price, are not the same we will see NWBO charge to meet NICE guidelines.

They could charge up to 500K though and still meet NICE guidelines given 100K per QALY is the upper bound threshold for rare diseases.


Orphan Medicinal Products (OMPs) for rare diseases undergo health technology appraisals (HTA) by the National Institute for Health and Care Excellence (NICE). Drugs for ‘very rare’ conditions undergo further extensive Highly Specialized Technology (HST) reviews, to establish the overall magnitude of their therapeutic benefits, cost effectiveness, and budget impact. On April 1, 2017, NICE published an incremental cost-effectiveness ratio (ICER) threshold for OMPs set at £100,000 per quality-adjusted-life-year (QALY) gained, in addition to a QALY weighting dependent on the QALY gain offered by the new treatment.



https://www.valueinhealthjournal.com/article/S1098-3015(17)31915-0/fulltext


Following changes introduced in April 2017, NICE set a maximum additional QALY threshold of £300,000 for highly specialised treatments, under which they will automatically be approved for routine commissioning. This is ten times higher than the standard NICE threshold of £30,000 for non-specialised treatments. The upper limit will vary according to the lifelong impact of the technology on the patient, varying from £100,000 per quality-adjusted life year for treatments that deliver less than 10 QALYs to the patient in their lifetime, up to a maximum of £300,000 for treatments that deliver more than 30 additional QALYs to the patient in their lifetime.



https://researchbriefings.files.parliament.uk/documents/CDP-2019-0022/CDP-2019-0022.pdf



We can keep going back and forth or continue yacht shopping.


Which do you prefer?